References
- Tefferi A, Patnaik MM, Pardanani A. Eosinophilia:secondary, clonal and idiopathic. Br J Haematol 2006;133:468–492.
- Walsh GM. Advances in the immunobiology of eosinophils and their role in disease. Crit Rev Clin Lab Sci 1999;36:453–496.
- Helbig G, Kyrcz-Krzemień S. Diagnostic and therapeutic management in patients with hypereosinophilic syndrome. Pol Arch Med Wewn 2011;121:44–52.
- Chusid MJ, Dale CD, West BC, . The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1–27.
- Valent P, Klion A, Horny HP, . Contemprorary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607–612.
- Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759–2779.
- Ogbogu PU, Bochner BS, Butterfield JH, . Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;121:1319–1325.
- Klion AD, Bochner BS, Gleich GJ. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006;117:1292–1302.
- Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica 2009;94:1188–1193.
- Valent P, Gleich GJ, Reiter A, . Pathogenesis and classification of eosinophil disorders:a review of recent developments in the field. Expert Rev Hematol 2012;159:1–5.
- Helbig G, Moskwa A, Hus M, . Heterogeneity among characteristics of hypereosinophilic syndromes. J Allergy Clin Immunol 2010;125:1399–1400.
- Rothenberg ME, Klion AD, Roufosse F, . Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215–1228.
- Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:333–355.
- Helbig G, Hus M, Hałasz M, . Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRA-negative hypereosinophilic syndrome. Med Oncol 2012;29:1073–1076.
- Jain N, Cortes J, Quintas-Cardama A, . Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown and negative PDGFRA mutation status. Leuk Res 2009;33: 837–839.
- Baccarani M, Cilloni D, Rondoni M, . The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of multicenter prospective study. Haematologica 2007;92:1173–1179.
- Bush RK, Geller M, Busse WW, . Response to corticosteroids in the hypereosinophilic syndrome: association with increased serum IgE levels. Arch Intern Med 1978;138:1244–1246.
- Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010;85:158–164.